A Phase 3 Trial of Epcoritamab in R/R DLBCL
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diffuse Large B Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The purpose of this trial is to evaluate the efficacy of epcoritamab (GEN3013 DuoBody®-CD3xCD20) compared to investigator's choice of chemotherapy in patients with relapsed, refractory diffuse large B-Cell Lymphoma who have failed or are ineligible for HDT-ASCT. Eligible patients will be randomized ...
The purpose of this trial is to evaluate the efficacy of epcoritamab (GEN3013 DuoBody®-CD3xCD20) compared to investigator's choice of chemotherapy in patients with relapsed, refractory diffuse large B-Cell Lymphoma who have failed or are ineligible for HDT-ASCT. Eligible patients will be randomized (1:1) to either epcoritamab or investigator's choice of chemotherapy: R-GemOx (rituximab, gemcitabine and oxaliplatin) or BR (bendamustine and rituximab).
Tracking Information
- NCT #
- NCT04628494
- Collaborators
- AbbVie
- Investigators
- Not Provided
Get Well Soon